Telos Capital Management Inc. Buys 479 Shares of ResMed Inc. (NYSE:RMD)

Telos Capital Management Inc. lifted its stake in ResMed Inc. (NYSE:RMD) by 1.6% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 30,377 shares of the medical equipment provider’s stock after purchasing an additional 479 shares during the quarter. Telos Capital Management Inc.’s holdings in ResMed were worth $7,416,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Wellington Management Group LLP purchased a new position in ResMed during the fourth quarter valued at approximately $7,535,000. Park Avenue Securities LLC lifted its stake in shares of ResMed by 20.3% during the 1st quarter. Park Avenue Securities LLC now owns 2,266 shares of the medical equipment provider’s stock valued at $449,000 after buying an additional 382 shares in the last quarter. Ballentine Partners LLC boosted its holdings in ResMed by 19.1% in the 1st quarter. Ballentine Partners LLC now owns 1,545 shares of the medical equipment provider’s stock worth $306,000 after buying an additional 248 shares during the period. Riverview Trust Co bought a new position in ResMed in the 1st quarter worth $42,000. Finally, Agate Pass Investment Management LLC purchased a new stake in ResMed in the 1st quarter worth $225,000. 54.98% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, insider Justin Leong sold 48,000 shares of the business’s stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $217.07, for a total transaction of $10,419,360.00. Following the transaction, the insider now owns 18,741 shares of the company’s stock, valued at approximately $4,068,108.87. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, insider Justin Leong sold 48,000 shares of ResMed stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $217.07, for a total transaction of $10,419,360.00. Following the completion of the transaction, the insider now directly owns 18,741 shares of the company’s stock, valued at approximately $4,068,108.87. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Brett Sandercock sold 1,000 shares of the company’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $212.16, for a total transaction of $212,160.00. Following the transaction, the chief financial officer now owns 89,056 shares in the company, valued at $18,894,120.96. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 123,874 shares of company stock valued at $28,151,142 in the last ninety days. Insiders own 0.71% of the company’s stock.

ResMed Trading Up 0.0 %

Shares of RMD opened at $240.05 on Tuesday. The stock has a market capitalization of $35.23 billion, a PE ratio of 34.64, a P/E/G ratio of 2.15 and a beta of 0.69. The company’s fifty day moving average is $239.29 and its 200 day moving average is $216.70. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.69 and a current ratio of 2.59. ResMed Inc. has a fifty-two week low of $132.24 and a fifty-two week high of $255.18.

ResMed (NYSE:RMD) last posted its earnings results on Thursday, August 1st. The medical equipment provider reported $2.08 earnings per share for the quarter, topping analysts’ consensus estimates of $2.03 by $0.05. The firm had revenue of $1.20 billion for the quarter, compared to the consensus estimate of $1.22 billion. ResMed had a net margin of 21.79% and a return on equity of 25.00%. The business’s quarterly revenue was up 6.9% on a year-over-year basis. During the same period in the previous year, the firm posted $1.60 EPS. Sell-side analysts expect that ResMed Inc. will post 9.08 earnings per share for the current fiscal year.

ResMed Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 19th. Shareholders of record on Thursday, August 15th were given a dividend of $0.53 per share. The ex-dividend date was Thursday, August 15th. This is an increase from ResMed’s previous quarterly dividend of $0.48. This represents a $2.12 dividend on an annualized basis and a yield of 0.88%. ResMed’s dividend payout ratio is 30.59%.

Analyst Ratings Changes

RMD has been the topic of several research analyst reports. Baird R W upgraded ResMed to a “strong-buy” rating in a research report on Tuesday, September 24th. StockNews.com raised ResMed from a “hold” rating to a “buy” rating in a report on Tuesday, October 15th. Royal Bank of Canada increased their price objective on shares of ResMed from $206.00 to $224.00 and gave the company a “sector perform” rating in a report on Tuesday, October 1st. Wolfe Research reiterated an “underperform” rating and set a $180.00 price objective on shares of ResMed in a research report on Wednesday, September 18th. Finally, Citigroup downgraded shares of ResMed from a “buy” rating to a “neutral” rating in a report on Monday, June 24th. One analyst has rated the stock with a sell rating, five have given a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $218.18.

ResMed Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.